Who are continue cozaar's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): start cozaar, Losartan Tablets, Cozaar® plus pro tab, Angiotensin II Receptor Antagonists.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/continue-cozaar.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

continue cozaar — Competitive Intelligence Brief

continue cozaar (continue cozaar) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor antagonist (ARB). Area: Cardiovascular.

marketed Angiotensin II receptor antagonist (ARB) AT1 receptor (Angiotensin II Type 1 receptor) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

continue cozaar (continue cozaar) — University of Pittsburgh. Cozaar (losartan) blocks angiotensin II receptors on blood vessels and tissues, causing vasodilation and reducing blood pressure.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
continue cozaar TARGET	continue cozaar	University of Pittsburgh	marketed	Angiotensin II receptor antagonist (ARB)	AT1 receptor (Angiotensin II Type 1 receptor)
start cozaar	start cozaar	University of Pittsburgh	marketed	Angiotensin II receptor antagonist (ARB)	AT1 receptor (angiotensin II type 1 receptor)
Losartan Tablets	Losartan Tablets	Istituto Auxologico Italiano	marketed	Angiotensin II receptor antagonist (ARB)	AT1 receptor (angiotensin II type 1 receptor)
Cozaar® plus pro tab	Cozaar® plus pro tab	Hanmi Pharmaceutical Company Limited	marketed	Angiotensin II receptor antagonist (ARB)	AT1 receptor (angiotensin II type 1 receptor)
Angiotensin II Receptor Antagonists	Angiotensin II Receptor Antagonists	Nara Medical University	marketed	Angiotensin II receptor antagonist (ARB)	AT1 receptor (Angiotensin II type 1 receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor antagonist (ARB) class)

University of Pittsburgh · 2 drugs in this class
Hanmi Pharmaceutical Company Limited · 1 drug in this class
Istituto Auxologico Italiano · 1 drug in this class
Nara Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). continue cozaar — Competitive Intelligence Brief. https://druglandscape.com/ci/continue-cozaar. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab